Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1 : A Case Presentation and Review of the Literature

The outbreak of COVID-19 pandemia is a major health worldwide concern. Patients with cancer might have a worse outcome, because of the immunosuppression determined by the tumor itself and anti-cancer treatments, including chemotherapy and radiotherapy. The impact and course of viral infection in patients receiving immunotherapy remains unknown. We report the case of a patient with metastatic melanoma, long responder to anti PD-1 blockade who got infected with Sars CoV-2, recovering without sequelae. A critical review of literature was performed. Limited data available in literature support the possibility to continue the immunotherapy in patients with cancer under control.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:39

Enthalten in:

Cancer investigation - 39(2021), 1 vom: 01. Jan., Seite 9-14

Sprache:

Englisch

Beteiligte Personen:

Pala, Laura [VerfasserIn]
Conforti, Fabio [VerfasserIn]
Cocorocchio, Emilia [VerfasserIn]
Ferrucci, Pierfrancesco [VerfasserIn]
De Pas, Martino Tommaso [VerfasserIn]
Stucchi, Sara [VerfasserIn]
Repetto, Matteo [VerfasserIn]
Saponara, Maristella [VerfasserIn]
Queirolo, Paola [VerfasserIn]

Links:

Volltext

Themen:

Anti-PD-1
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
COVID-19
Cancer
Case Reports
DPT0O3T46P
Immune Checkpoint Inhibitors
Journal Article
Melanoma
Pembrolizumab
Review

Anmerkungen:

Date Completed 25.01.2021

Date Revised 25.01.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1080/07357907.2020.1844893

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM316938041